Farrell Michael J., CEO of ResMed (RMD) and a director at Zimmer Biomet (ZBH), has demonstrated a clear selling bias in recent insider transactions, with no open-market purchases recorded in the past year. Since September 2025, Farrell has executed seven sales of RMD stock totaling approximately $10.6 million, including a $2.27 million disposition on October 7, 2025, and a $2 million sale on November 7, 2025. The transactions follow a consistent pattern of monthly sales from December 2025 through March 2026, each accompanied by smaller acquisitions through derivative transactions coded as "M," likely representing option exercises. Notably, Farrell acquired $8.34 million in RMD shares via an "A"-coded transaction on November 24, 2025, though this appears related to equity awards rather than open-market buying. His activity in Zimmer Biomet (ZBH) has been limited to annual award grants with no market transactions. Overall, Farrell's $29.87 million in lifetime sell-value across 41 transactions significantly outweighs his $19.45 million in buys, with the recent activity reinforcing a distribution-focused approach to his ResMed holdings. The sales occur at regular intervals, suggesting a structured divestment plan rather than reactionary trading.
AI-assisted summary